局部晚期宫颈癌患者报告急性胃肠症状与直肠剂量相关
该前瞻性队列纳入103例局部晚期宫颈癌患者,接受基于计划库的每日计划方案放疗,同步化疗或新辅助化疗加同期热疗。每周问卷提取急性胃肠症状,结合剂量表面图分析,发现同步化疗和PTV增大显著增加腹泻报告,直肠V5Gy-V25Gy及下段直肠剂量与腹泻显著相关。
要点
- 同步化疗和PTV增大显著增加患者报告的腹泻。
- 直肠V5Gy-V25Gy与腹泻显著相关,肠袋剂量参数无显著关联。
- 报告腹泻患者的下段直肠剂量显著更高。
核心结论
- 同步化疗可能通过放疗增敏效应增加患者报告的腹泻症状。
- 降低下段直肠剂量可能减少患者报告的腹泻症状。
- PTV体积与腹泻症状的显著关联提示每日计划方案可能带来获益。
研究设计与样本
- 前瞻性队列研究,共纳入103例局部晚期宫颈癌患者。
- 放疗基于计划库的每日计划方案,联合同步化疗或新辅助化疗加同期热疗。
- 治疗期间每周及治疗后急性期定期发放问卷提取毒性终点。
- 构建直肠剂量表面图,收集肠袋和直肠的临床与剂量参数。
主要发现
- 同步化疗和PTV增大导致报告的腹泻显著增加。
- 直肠V5Gy-V25Gy剂量体积参数与腹泻显著相关,肠袋剂量体积参数无显著关联。
- 报告腹泻的患者下段直肠剂量显著更高。
- 粪漏和肠绞痛未达到显著性。
关键数值与推荐
- 腹泻分析中直肠V5Gy-V25Gy为显著相关剂量体积参数。
- 同步化疗和PTV增大与腹泻报告显著增加相关。
- 下段直肠剂量在报告腹泻患者中显著更高。
临床怎么用
- 制定放疗计划时关注直肠V5Gy-V25Gy和下段直肠剂量,可能有助于减少急性腹泻。
- 对接受同步化疗的患者应加强急性胃肠症状监测与管理。
- 每日计划方案可能通过优化PTV覆盖而减少腹泻症状,值得进一步评估。
局限性
- 粪漏和肠绞痛未达到显著性,相关分析受限。
- 样本量有限,结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To investigate relationships between patient-reported acute gastro-intestinal symptoms in a locally advanced cervical cancer (LACC) prospective cohort and clinical and dosimetric parameters, while also taking spatial dose into account. MATERIAL AND METHODS: A total of 103 patients was included, receiving radiotherapy based on a plan-library-based plan-of-the-day protocol, combined either with concurrent chemotherapy or with neo-adjuvant chemotherapy and concomitant hyperthermia. Toxicity endpoints were extracted from questionnaires sent out weekly during treatment and regularly in the acute phase after treatment. Endpoints were defined for symptoms concerning obstipation, diarrhea, fecal leakage, bowel cramps and rectal bleeding. Dose surface maps were constructed for the rectum. Clinical parameters and dosimetric parameters of the bowel bag and rectum were collected for all patients. RESULTS: The use of concomitant chemotherapy and an increase in Planning Target Volume (PTV) resulted in a significant increase in reported diarrhea. The dose-volume parameters V5Gy-V25Gy of the rectum were found to be significant, unlike dose-volume parameters of the bowel bag. Additionally, a significantly higher dose to the inferior part of the rectum was found for patients reporting diarrhea. No significance was reached for fecal leakage and bowel cramps. CONCLUSION: The significance of results for patients reporting diarrhea symptoms found for PTV volume indicates a potential benefit for a plan-of-the-day protocol. Additionally, the results suggest that a reduction of inferior rectum dose could decrease patient-reported diarrhea symptoms, while the administration of concomitant chemotherapy appears to lead to radiosensitizing effects that increase these symptoms.
引用
- Reijtenbagh DMW, Godart J, Mens JM, et al. Patient-reported acute GI symptoms in locally advanced cervical cancer patients correlate with rectal dose. Radiother Oncol. 2020. PMID: 32311599. doi:10.1016/j.radonc.2020.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。